Oxford BioDynamics PLC
Oxford BioDynamics (OBD) is a biotechnology company specializing in precision medicine and biomarker discovery. The company operates primarily in the healthcare sector, focusing on developing and commercializing innovative diagnostic tests based on its proprietary EpiSwitch platform, which assesses epigenetic biomarkers. OBD aims to enhance patient stratification and treatment outcomes in various diseases, including cancer and autoimmune disorders, by providing accurate, reliable, and actionable insights for clinicians and researchers.